Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019

Decisions on market authorization (MA) and reimbursement have different durations across countries because of health technology assessment (HTA) procedures and negotiations between manufacturers and national authorities. To overcome this delay, France has implemented a Temporary Authorization for Us...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Fiona Y.‐V., Jacquet, Emmanuelle, Taleb, Amina, Monard, Adrien, Kerouani‐Lafaye, Ghania, Turcry, Florence, Brunel, Liora, Grudé, Françoise, Yoldjian, Isabelle, Sainte‐Marie, Isabelle, Boudali, Lotfi, Blay, Jean‐Yves, Albin, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540593/
https://www.ncbi.nlm.nih.gov/pubmed/35603979
http://dx.doi.org/10.1002/ijc.34129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540593/
https://www.ncbi.nlm.nih.gov/pubmed/35603979
http://dx.doi.org/10.1002/ijc.34129

Ejemplares similares